亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho

医学 氢氯噻嗪 血压 耐受性 药丸 氨氯地平 氯沙坦 随机对照试验 内科学 中止 不利影响 血管紧张素II 药理学
作者
Herry Mapesi,Martin Rohacek,Fiona Vanobberghen,Ravi Gupta,Herieth Ismael Wilson,Blaise Lukau,Alain Amstutz,Aza Lyimo,Josephine Muhairwe,Elizabeth Senkoro,Theonestina Byakuzana,Jacqueline Nkouabi,Geofrey Mbunda,Jamali Siru,A. Tarr,Elsie Ramapepe,Madavida Mphunyane,Johanna Oehri,Valeriya Nemtsova,Xiaohan Yan,Moniek Bresser,Tracy R. Glass,Daniel H. Paris,Günther Fink,Winfrid Gingo,Niklaus Daniel Labhardt,Thilo Burkard,Maja Weisser
出处
期刊:JAMA Cardiology [American Medical Association]
标识
DOI:10.1001/jamacardio.2024.5124
摘要

Importance Hypertension is the primary cardiovascular risk factor in Africa. Recently revised World Health Organization guidelines recommend starting antihypertensive dual therapy; clinical efficacy and tolerability of low-dose triple combination remain unclear. Objectives To compare the effect of 3 treatment strategies on blood pressure control among persons with untreated hypertension in Africa. Design, Setting, and Participants This was an open-label, parallel, 3-arm randomized clinical trial to evaluate noninferiority of a strategy starting 2 pills vs full-dose monotherapy with stepped escalation (noninferiority margin 10%) and superiority of starting low-dose 3 pills vs monotherapy allowing for monthly up titration. Recruitment lasted from March 5, 2020, to March 30, 2022. The setting was 2 hospitals in rural Lesotho and Tanzania. Participants included nonpregnant Black African individuals 18 years and older with uncomplicated, untreated hypertension (standardized office blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic). Interventions Participants were randomized 2:2:1 to stepped monotherapy (amlodipine, 10 mg, with escalation to add hydrochlorothiazide if needed), 2-pill strategy (amlodipine, 5 mg; losartan, 25 mg), or 3-pill strategy (amlodipine, 2.5 mg; losartan, 12.5 mg; hydrochlorothiazide, 6.25 mg). Drugs were up titrated monthly until reaching the target blood pressure (≤ 130/80 mm Hg for participants aged <65 years; ≤140/90 mm Hg for those aged ≥65 years). Main Outcomes and Measures Proportion of participants reaching target blood pressure at 12 weeks. Results Of 1761 participants screened, 1268 were enrolled (median [IQR] age, 54 [45-65] years; 914 female [72%]), with 505 in the monotherapy cohort, 510 in the 2-pill cohort, and 253 in the 3-pill cohort. In noninferiority analyses, 207 of 370 participants (56%) receiving the 2-pill strategy and 173 of 338 participants (51%) receiving the stepped monotherapy strategy achieved the blood pressure target (adjusted odds ratio [aOR], 1.18; 95% CI, 0.87-1.61), fulfilling noninferiority. In superiority analyses after multiple imputation for missing outcome data, 57% of participants receiving the 3-pill strategy, 55% receiving the 2-pill strategy, and 49% receiving the stepped monotherapy strategy reached the target blood pressure (aOR, 1.24; 95% CI, 0.94-1.63; P = .12 and aOR, 1.28; 95% CI, 0.91-1.79; P = .16 for the 2-pill and 3-pill vs stepped monotherapy strategies, respectively). Conclusions and Relevance Results of this randomized clinical trial show that in 2 African settings, for adults with uncomplicated untreated hypertension, a strategy starting a 2-pill low-dose treatment was noninferior to starting stepped monotherapy. Two-pill and 3-pill low-dose strategies were not superior to stepped monotherapy. Wide CIs preclude the ability to rule out potentially clinically important effects of the additional pill strategies for hypertension control. Trial Registration ClinicalTrials.gov Identifier: NCT04129840
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
满意访冬完成签到,获得积分20
27秒前
33秒前
科研通AI5应助满意访冬采纳,获得10
36秒前
渡己完成签到 ,获得积分10
38秒前
Oracle应助bruna采纳,获得100
54秒前
wanjingwan完成签到 ,获得积分10
1分钟前
1分钟前
提桶跑路完成签到 ,获得积分10
1分钟前
1分钟前
满意访冬发布了新的文献求助10
1分钟前
于清绝完成签到 ,获得积分10
2分钟前
昏睡的乌冬面完成签到 ,获得积分10
2分钟前
小白菜完成签到,获得积分10
2分钟前
浮生若梦完成签到,获得积分10
2分钟前
搜集达人应助YD采纳,获得10
2分钟前
3分钟前
YD发布了新的文献求助10
3分钟前
3分钟前
Dannnn发布了新的文献求助10
3分钟前
潇洒新筠发布了新的文献求助10
3分钟前
stuuuuuuuuuuudy完成签到 ,获得积分10
4分钟前
asdwind完成签到,获得积分10
4分钟前
little完成签到,获得积分10
4分钟前
喜悦的小土豆完成签到 ,获得积分10
5分钟前
loen完成签到,获得积分10
5分钟前
小二郎应助科研通管家采纳,获得10
5分钟前
5分钟前
yang完成签到,获得积分10
5分钟前
隐形曼青应助yang采纳,获得10
5分钟前
谨慎颜演完成签到 ,获得积分10
5分钟前
奋斗水香完成签到,获得积分10
6分钟前
牛八先生完成签到,获得积分10
6分钟前
加绒完成签到,获得积分10
7分钟前
Sesenta1发布了新的文献求助10
7分钟前
神勇朝雪完成签到,获得积分10
8分钟前
小西完成签到 ,获得积分10
9分钟前
tao ism完成签到 ,获得积分10
9分钟前
科研狂人完成签到,获得积分10
9分钟前
热心的飞风完成签到 ,获得积分10
9分钟前
汉堡包应助科研通管家采纳,获得10
9分钟前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
the MD Anderson Surgical Oncology Manual, Seventh Edition 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3777609
求助须知:如何正确求助?哪些是违规求助? 3322969
关于积分的说明 10212809
捐赠科研通 3038316
什么是DOI,文献DOI怎么找? 1667308
邀请新用户注册赠送积分活动 798103
科研通“疑难数据库(出版商)”最低求助积分说明 758229